LabCorp

LHPhase 2

Laboratory Corporation of America Holdings (LabCorp) is a Fortune 500 life sciences company that advances health and improves lives by delivering world-class diagnostics, drug development, and technology solutions. With over 75,000 employees globally, LabCorp combines the world's largest clinical laboratory network with comprehensive drug development capabilities, from discovery through post-market studies. The company serves healthcare providers, biopharmaceutical companies, government agencies, managed care organizations, hospitals, and patients in more than 100 countries.

Market Cap

$21.7B

Employees

70,000-80,000

Focus

Biotech

LH · Stock Price

USD 263.00+27.64 (+11.74%)

Historical price data

AI Company Overview

Technology Platform

LabCorp operates one of the world's largest clinical laboratory networks with advanced automation, AI-powered diagnostics, and comprehensive drug development capabilities spanning discovery through post-market studies.

Pipeline Snapshot

9 drugs in pipeline

Drug	Indication	Stage
VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + Placebo	Beta-Thalassemia	Phase 2
VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + Placebo	Beta-Thalassemia	Phase 2
Infigratinib	Advanced Solid Tumor	Phase 1/2
EMB-01 + Osimertinib	Metastatic Lung Non-Small Cell Carcinoma	Phase 1/2
EMB-01	Neoplasms	Phase 1/2

Opportunities

LabCorp is positioned to capitalize on the growing demand for personalized medicine, AI-powered diagnostics, and decentralized healthcare services.

The company's vast data repository and laboratory network provide significant competitive advantages in developing next-generation diagnostic solutions.

Risk Factors

Key risks include regulatory changes affecting reimbursement, increased competition from technology companies, cybersecurity threats, and potential economic downturns reducing healthcare utilization.

The company also faces integration challenges from its acquisition-heavy growth strategy.

Competitive Landscape

LabCorp competes primarily with Quest Diagnostics in clinical laboratory services and with major CROs like IQVIA and PPD in drug development. The company differentiates through its integrated platform combining diagnostics and drug development capabilities, though the 2023 Fortrea spin-off has changed this dynamic.

Publications

Patents

Pipeline